{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:57:38Z","timestamp":1792501058301,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.cgh.2017.11.050","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T12:01:21Z","timestamp":1512648081000},"page":"697-705.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Association of Vedolizumab Level, Anti-Drug Antibodies, and \u03b14\u03b27 Occupancy With Response in Patients With Inflammatory Bowel Diseases"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-2249","authenticated-orcid":false,"given":"Bella","family":"Ungar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Yavzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coscas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Haj-Natour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Orbach-Zingboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Eliakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.11.050_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/gut.25.1.32","article-title":"Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques","volume":"25","author":"Selby","year":"1984","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.11.050_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-011-0104-6","article-title":"Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis","volume":"20","author":"Thomas","year":"2012","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cgh.2017.11.050_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/331041a0","article-title":"A\u00a0tissue-specific endothelial cell molecule involved in lymphocyte homing","volume":"331","author":"Streeter","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2017.11.050_bib4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort","volume":"21","author":"Shelton","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2017.11.050_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.11.050_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1756283X16638833","article-title":"Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Kopylov","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2017.11.050_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.11.050_bib8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.11.050_bib9","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1097\/MIB.0b013e3182a77b41","article-title":"Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study","volume":"19","author":"Paul","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2017.11.050_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.050_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.050_bib12","unstructured":"Agency EM. Assessment report\u2013Entyvio, 2014."},{"key":"10.1016\/j.cgh.2017.11.050_bib13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40261-016-0437-4","article-title":"Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers","volume":"36","author":"Rosario","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cgh.2017.11.050_bib14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/gut.2004.056358","article-title":"Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis","volume":"54","author":"Higgins","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.11.050_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A\u00a0simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2017.11.050_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.11.050_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/ecco-jcc\/jjw067","article-title":"Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab","volume":"10","author":"Papamichael","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2017.11.050_bib18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.11.050_bib19","first-page":"593","article-title":"Comparable immune function inhibition by the infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease","volume":"11","author":"Lim","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2017.11.050_bib20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.11.050_bib21","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2013a nationwide consecutive German cohort study","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.11.050_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.11.050_bib23","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cgh.2017.11.050_bib24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn's disease","volume":"11","author":"Rosario","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2017.11.050_bib25","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases with need for additional doses within 6 months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.11.050_bib26","article-title":"Vedolizumab exposure correlates with clinical, biological and endoscopic outcome in patients with inflammatory bowel disease","volume":"2","author":"Vermeire","year":"2016","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.cgh.2017.11.050_bib27","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2017.11.050_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/cyto.b.21236","article-title":"Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab","volume":"90","author":"Wyant","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.cgh.2017.11.050_bib29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to etrolizumab and expression of integrin alphaE and granzyme A in colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.11.050_bib30","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0016-5085(17)30493-6","article-title":"Integrin \u03b14\u03b27 expression preceding and saturation during vedolizumab therapy correlate with treatment response in inflammatory bowel disease","volume":"152","author":"Boden","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517314234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517314234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:24:08Z","timestamp":1761542648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517314234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1542356517314234"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.11.050","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732279401.793562778","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Vedolizumab Level, Anti-Drug Antibodies, and \u03b14\u03b27 Occupancy With Response in Patients With Inflammatory Bowel Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.11.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}